165 related articles for article (PubMed ID: 18809221)
21. Hormesis in Cholestatic Liver Disease; Preconditioning with Low Bile Acid Concentrations Protects against Bile Acid-Induced Toxicity.
Verhaag EM; Buist-Homan M; Koehorst M; Groen AK; Moshage H; Faber KN
PLoS One; 2016; 11(3):e0149782. PubMed ID: 26950211
[TBL] [Abstract][Full Text] [Related]
22. Resistance of rat hepatocytes against bile acid-induced apoptosis in cholestatic liver injury is due to nuclear factor-kappa B activation.
Schoemaker MH; Gommans WM; Conde de la Rosa L; Homan M; Klok P; Trautwein C; van Goor H; Poelstra K; Haisma HJ; Jansen PL; Moshage H
J Hepatol; 2003 Aug; 39(2):153-61. PubMed ID: 12873810
[TBL] [Abstract][Full Text] [Related]
23. Phosphatidylinositol-3-kinase p110γ contributes to bile salt-induced apoptosis in primary rat hepatocytes and human hepatoma cells.
Hohenester S; Gates A; Wimmer R; Beuers U; Anwer MS; Rust C; Webster CR
J Hepatol; 2010 Nov; 53(5):918-26. PubMed ID: 20675006
[TBL] [Abstract][Full Text] [Related]
24. Anti-inflammatory effects of leflunomide on cultured synovial macrophages from patients with rheumatoid arthritis.
Cutolo M; Sulli A; Ghiorzo P; Pizzorni C; Craviotto C; Villaggio B
Ann Rheum Dis; 2003 Apr; 62(4):297-302. PubMed ID: 12634225
[TBL] [Abstract][Full Text] [Related]
25. Mechanism of the antiproliferative action of leflunomide. A77 1726, the active metabolite of leflunomide, does not block T-cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides.
Cao WW; Kao PN; Chao AC; Gardner P; Ng J; Morris RE
J Heart Lung Transplant; 1995; 14(6 Pt 1):1016-30. PubMed ID: 8719445
[TBL] [Abstract][Full Text] [Related]
26. Differential modulation of pro- and anti-inflammatory cytokine receptors by N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxy-crotonic acid amide (A77 1726), the physiologically active metabolite of the novel immunomodulator leflunomide.
Mirmohammadsadegh A; Homey B; Abts HF; Köhrer K; Ruzicka T; Michel G
Biochem Pharmacol; 1998 May; 55(9):1523-9. PubMed ID: 10076546
[TBL] [Abstract][Full Text] [Related]
27. The active metabolite of leflunomide, A77 1726, inhibits the production of prostaglandin E(2), matrix metalloproteinase 1 and interleukin 6 in human fibroblast-like synoviocytes.
Burger D; Begué-Pastor N; Benavent S; Gruaz L; Kaufmann MT; Chicheportiche R; Dayer JM
Rheumatology (Oxford); 2003 Jan; 42(1):89-96. PubMed ID: 12509619
[TBL] [Abstract][Full Text] [Related]
28. Sensitization of human hepatic stellate cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by leflunomide.
Tang X; Yang J; Li J
Biol Pharm Bull; 2009 Jun; 32(6):963-7. PubMed ID: 19483299
[TBL] [Abstract][Full Text] [Related]
29. A77 1726, the active metabolite of the anti-rheumatoid arthritis drug leflunomide, inhibits influenza A virus replication in vitro and in vivo by inhibiting the activity of Janus kinases.
Wang J; Sun J; Hu J; Wang C; Prinz RA; Peng D; Liu X; Xu X
FASEB J; 2020 Aug; 34(8):10132-10145. PubMed ID: 32598086
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide.
Mattar T; Kochhar K; Bartlett R; Bremer EG; Finnegan A
FEBS Lett; 1993 Nov; 334(2):161-4. PubMed ID: 8224241
[TBL] [Abstract][Full Text] [Related]
31. In vitro metabolism of leflunomide by mouse and human liver microsomes.
Chan EC; New LS
Drug Metab Lett; 2007 Dec; 1(4):299-305. PubMed ID: 19356059
[TBL] [Abstract][Full Text] [Related]
32. Leflunomide: mode of action in the treatment of rheumatoid arthritis.
Breedveld FC; Dayer JM
Ann Rheum Dis; 2000 Nov; 59(11):841-9. PubMed ID: 11053058
[TBL] [Abstract][Full Text] [Related]
33. Leflunomide and malononitrilamides.
Silva Júnior HT; Morris RE
Am J Med Sci; 1997 May; 313(5):289-301. PubMed ID: 9145039
[TBL] [Abstract][Full Text] [Related]
34. Superoxide anions and hydrogen peroxide induce hepatocyte death by different mechanisms: involvement of JNK and ERK MAP kinases.
Conde de la Rosa L; Schoemaker MH; Vrenken TE; Buist-Homan M; Havinga R; Jansen PL; Moshage H
J Hepatol; 2006 May; 44(5):918-29. PubMed ID: 16310883
[TBL] [Abstract][Full Text] [Related]
35. Leflunomide inhibits PDK1/Akt pathway and induces apoptosis of human mast cells.
Sawamukai N; Saito K; Yamaoka K; Nakayamada S; Ra C; Tanaka Y
J Immunol; 2007 Nov; 179(10):6479-84. PubMed ID: 17982036
[TBL] [Abstract][Full Text] [Related]
36. Prevention of bile acid-induced apoptosis by betaine in rat liver.
Graf D; Kurz AK; Reinehr R; Fischer R; Kircheis G; Häussinger D
Hepatology; 2002 Oct; 36(4 Pt 1):829-39. PubMed ID: 12297830
[TBL] [Abstract][Full Text] [Related]
37. Phosphoinositide 3-kinase, but not mitogen-activated protein kinase, pathway is involved in hepatocyte growth factor-mediated protection against bile acid-induced apoptosis in cultured rat hepatocytes.
Webster CR; Anwer MS
Hepatology; 2001 Mar; 33(3):608-15. PubMed ID: 11230741
[TBL] [Abstract][Full Text] [Related]
38. A 771726, the active metabolite of leflunomide, inhibits TNF-alpha and IL-1 from Kupffer cells.
Yao HW; Li J; Chen JQ; Xu SY
Inflammation; 2004 Apr; 28(2):97-103. PubMed ID: 15379215
[TBL] [Abstract][Full Text] [Related]
39. The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function.
Kirsch BM; Zeyda M; Stuhlmeier K; Grisar J; Smolen JS; Watschinger B; Stulnig TM; Hörl WH; Zlabinger GJ; Säemann MD
Arthritis Res Ther; 2005; 7(3):R694-703. PubMed ID: 15899055
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of nuclear factor kappaB and phosphatidylinositol 3-kinase/Akt is essential for massive hepatocyte apoptosis induced by tumor necrosis factor alpha in mice.
Imose M; Nagaki M; Naiki T; Osawa Y; Brenner DA; Asano T; Hayashi H; Kato T; Moriwaki H
Liver Int; 2003 Oct; 23(5):386-96. PubMed ID: 14708901
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
